NOVEL OXADIAZOLE COMPOUNDS CROSS REFERENCE TO RELATED APPLICATION This application claims priority to U.S. Provisional Application Serial No. 60/875,251 filed on December 15, 2006. BACKGROUND OF THE INVENTION Sphingosine-1-phosphate (SIP) is part of sphingomyelin biosynthetic pathway and is known to affect multiple biological processes. SIP is formed through phosphorylation of sphingosine by sphingosine kinases (SKI and SK2) and it is degraded through cleavage by sphingosine lyase to form palmitaldehyde and phosphoethanolamine or through dephosphorylation by phospholipid phosphatases. It is present at high levels (-500 nM) in serum and it is found in most tissues. It can be synthesized in a wide variety of cells in response to several stimuli, which include cytokines, growth factors and G protein-coupled receptor (GPCR) ligands. The GPCRs that bind SIP (currently know as the SIP receptors SIP 1-5), couple through pertusis toxin sensitive (Gi) pathways as well as pertusis toxin insensitive pathways to stimulate a variety of processes. The individual receptors of the SIP family are both tissue and response specific and so are attractive as therapeutic targets. SIP evokes many responses from cells and tissues. In particular, SlP has been shown to be an agonist at all five GPCRs, S1P1 (Edg-1), S1P2 (Edg-5), S1P3 (Edg-3), S1P4 (Edg-6) and S1P5 (Edg-8). The action of SIP at the SIP receptors has been linked to resistance to apoptosis, changes in cellular morphology, cell migration, growth, differentiation, cell division, angiogenesis and modulation of the immune system via alterations of lymphocyte trafficking. Therefore, SIP receptors are targets for therapy of, for example, neoplastic diseases, autoimmune disorders and tissue rejection in transplantation. These receptors also share 50-55% amino acid identity with three other lysophospholipid receptors, LPA1, LPA2, and LPA3 of the structurally related lysophosphatidic acid (LPA). GPCRs are excellent drug targets with numerous examples of marketed drugs across multiple disease areas. GPCRs are cell surface receptors that bind hormones on the extracellular surface of the cell and transduce a signal across the cellular membrane to the inside of the cell. The internal signal is amplified through interaction with G proteins which in turn interact with various second messenger pathways. This transduction pathway is manifested in downstream cellular responses that include cytoskeletal changes, cell motility, proliferation, apoptosis, secretion and regulation of protein expression to name a few. SIP receptors make good drug targets because individual receptors are expressed in different tissues and signal through different pathways making the individual receptors both tissue and response specific. Tissue specificity of the SIP receptors is desirable because development of an agonist or antagonist selective for one receptor localizes the cellular response to tissues containing that receptor, limiting unwanted side effects. Response specificity of the SIP receptors is also of importance because it allows for the development of agonists or antagonists that initiate or suppress certain cellular responses without affecting other responses. For example, the response specificity of the SIP receptors could allow for an SIP mimetic that initiates platelet aggregation without affecting cell morphology. The physiologic implications of stimulating individual SIP receptors are largely unknown due in part to a lack of receptor type selective ligands. Isolation and characterization of SIP analogs that have potent agonist or antagonist activity for SIP receptors have been limited. S1P1 for example is widely expressed and the knockout causes embryonic lethality due to large vessel rupture. Adoptive cell transfer experiments using lymphocytes from SEP1 knockout mice have shown that SI PI deficient lymphocytes sequester to secondary lymph organs. Conversely, T cells overexpressing S1P1 partition preferentially into the blood compartment rather than secondary lymph organs. These experiments provide evidence that S1P1 is the main sphingosine receptor involved in lymphocyte homing and trafficking to secondary lymphoid compartments Currently, there is a need for novel, potent, and selective agents, which are agonists or antagonists of the individual receptors of the SIP receptor family in order to address unmet medical needs associated with agonism or antagonism of the individual receptors of the SIP receptor family. SUMMARY OF THE INVENTION The present invention provides novel compounds described by general Formula (I), (la), (II), (III), (IV), (IVa) and (IVb) as agonists of the G protein-coupled receptor S1P1. These compounds reduce the number of circulating and infiltrating T- and B-lymphocytes affording a beneficial immunosuppressive effect. The compounds also exhibit activity within the SIP receptor family. In a first embodiment, the invention provides compound of Formula I (Formula Removed) pharmaceutically acceptable salts, biologically active metabolites, solvates, hydrates, prodrugs, enantiomers or stereoisomers thereof, wherein L is a bond or optionally substituted (C1-C3)alkyl; R' is -C(O)-NH-phenyl, -NH-C(O)-furanyl, -NH-S(O)2-optionally substituted phenyl, -O-optionally substituted (C1-C3)alkyl, -S-optionally substituted (C1-C3)alkyl, optionally substituted (C2-C6)alkyl, optionally substituted amino, optionally substituted (C3-C6)ycloalkyl, -(CH2)(C3)alkyl, tetrahydrobenzofuranyl, furanyl, tetrahydrofuranyl, optionally substituted 2,3-dihydroisoindolyl, optionally substituted imidazolyl, optionally substituted indolyl, optionally substituted isoxazolyl, optionally substituted morpholinyl, optionally substituted naphthyl, optionally substituted phenyl, -O-CH2-phenyl, -O-phenyl, -O-optionally substituted phenyl, optionally substituted piperidinyl, optionally substituted pyrazolyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrrolidinyl, optionally substituted 1,2,3,4-tetrahydroisoquinolinyl, optionally substituted quinolinyl, optionally substituted 5,6,7,8-tetrahydroirnidazo[l,2-a]pyrazinyl, optionally substituted pyrrolyl, optionally substituted quinolinyl, optionally substituted thiazolyl or optionally substituted thienyl; R2 is Br, Cl, CF3, CN, or -O-(C1-C2)alkyl; R3 is optionally substituted-(C3-C8)alkyl, (C4-C5)aIkenyl, (C4-C5)alkynyl, optionally substituted-{C3-C6)cycloalkyl, -(C2-C3)alkyl-O-optionally substituted (C1-C3)alkyl, -(C1-C3)alkyl-imidazolyl, -(C1-C3)alkyl-morpholinyl, -{C1-C3)alkyl-optionally substituted phenyl, -(C1-C3)aIkyl-optionally substituted piperazinyl, -(C1-C3)alkyl-pyrrolidinyl, -(C1-C3)alkyI-piperidinyl, -(C1-C3)alkyl-thienyl, tetrahydrofuranyl or thiazolyl; and R6 is H; provided that R1 is not substituted by optionally substituted cyclohexyl, -C(O)-cyclohexyl or-NH-cyclohexyl; when L is (C1-C3)alkyl, R1 is not optionally substituted isoxazolyl; when R3 is optionally substituted (C1)alkyl, L-R1 is not cyclohexyl or -CH2-cyclohexyl; and provided that the compound is not (Formula Removed) In a second embodiment the invention provides a compound of embodiment 1 wherein R1 is optionally substituted by one or more substituents independently selected from Br, Cl, F, CF3, CN, oxo, optionally substituted (C1-C6)alkyl, optionally substituted (C2-C6)alkenyl, optionally substituted amino, optionally substituted (C3-C6)cycloalkyl, -CH2-optionally substituted piperidinyl, -C(O)- optionally substituted (C1-C6)alkyl, -C(O)-NR-(C1-C6)alkyl, -C(O)-O-optionally substitutedC1-C6)alkyl, -O- optionally substituted (C1-C6)alkyl, -NH-(C3-C6)cycloalkyl, -NH-C(O)—O-{C1-C3)alkyl, -S(O)2-N(R9)2 -S(O)2-NH-optionally substituted (C1-C4)alkyl, -NH-optionally substituted(C1-C6)alkyl, -NH-C(O)-furanyl, -NH-S(O)2-optionally substituted phenyl, optionally substituted pyridinyl, (Formula Removed) wherein R is H or (C1-C3)alkyl; and wherein each R9 is independently selected from H or optionally substituted (C1-C6)alkyl. In a third embodiment, the invention provides compounds of any of the foregoing embodiments wherein the compound is a compound of Formula la (Formula Removed) wherein L is a bond. In a fourth embodiment the invention provides compounds of any of the foregoing embodiments wherein R1 is optionally substituted phenyl or optionally substituted indolyl. In a fifth embodiment the invention provides compounds of any of the foregoing embodiments wherein the compound is (Formula Removed) wherein y is 1 or 2. In a sixth embodiment the invention provides a compound according to any of the foregoing embodiments wherein L is optionally substituted (C1-C3)alkyl; R1 is -C(O)-NH-phenyl, -NH-C(O)-furanyl, -NH-S(O)2-OptionalIy substituted phenyl, optionally substituted -O-(C1-C3)alkyl, -S-(C1-C3)alkyI, benzyloxy, optionally substituted(C3-C6)cycloalkyl, optionally substituted imidazolyl, morpholinyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted piperazinyl, optionally substituted piperidinyl, optionally substituted pyridinyl, optionally substituted pyrrolidinyl or optionally substituted thienyl; R2 is CI; R3 is isopropyl; and R6 is H. In a seventh embodiment the invention provides compounds according to any of the foregoing embodiments wherein L is CH2 and R1 is optionally substituted phenyl or optionally substituted (C3-C6)cycIoalkyl. In an eighth embodiment the invention provides compounds according to claim 7 wherein R1 is substituted by one or more substituents independently selected from F, dimethylamino and phenoxy. In a ninth embodiment the invention provides compounds of formula II (Formula Removed) pharmaceutically acceptable salts, biologically active metabolites, solvates, hydrates, prodrugs, enantiomers or stereoisomers thereof, wherein Y is a bond; L is a bond or CH2; R1 is optionally substituted (C1-C4)alkyl, optionally substituted indolyl or optionally substituted phenyl; R2 is CF3; R3 is H, morpholinyl or (C3-C5)cycIoalkyl; and R6 is H. In a tenth embodiment the invention provides compounds according to the ninth embodiment wherein R1 is optionally substituted phenyl and R3 is morpholinyl. In an eleventh embodiment the invention provides compounds of according to embodiments nine and ten wherein R1 is optionally substituted by one or more substituents independently selected from Cl, optionally substituted (C1-C3)alkyl, (Formula Removed) In a twelfth embodiment the invention provides compounds of Formula III (Formula Removed) pharmaceutically acceptable salts, biologically active metabolites, solvates, hydrates, prodrugs, enantiomers or stereoisomers thereof, wherein D is CH or N; Y is a bond; L is a bond; R1 is optionally substituted phenyl; R2 is H; R3 is H; and R6 is optionally substituted (C1-C3)alkyl. In a thirteenth embodiment the invention provides compounds according to the twelfth embodiment wherein R1 is substituted with Cl and isopropoxy. In a fourteenth embodiment the invention provides compounds having formula (IV): (Formula Removed) or a pharmaceutically acceptable salt, solvate, hydrate, metabolite, prodrug, enantiomer or stereoisomer thereof, wherein: XisNorCR4; L is a bond, -CH2CH2-, (C3-C6)cycloalkyl, or -CHR5; Y is -O-, -MR7- or -C(R7)(R7')-; R1 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted -(C1-C6)alkyl-O-(C1-C3)alkyl, optionally substituted -(C1-C6)alkyl-O-(C1-C6)alkyl -O-(C1-C3)alkyl, optionally substituted -(C1-C6)alkyl-O-aryl, alkylsulfanylalkyl, unsubstituted (C2-C5)alkyl, substituted (C1-C6)alkyl, -COR9, optionally substituted -O-(C1-C3)alkyl, -N(R7)(R8), -N(R7)SO2-R9 or optionally substituted (C3-C6)cycloalkyl, and wherein R1 is not substituted cyclopentathiophene, halothiophene, substituted indan or substituted chromenone; R2 and R6 may be the same or different and are independently H, -(C1-C4)alkyl, -O-(C1-C3)alkyl, -CF3, -CN, halo or -COO-(C1-C4)alkyl; R3 is optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted (C3-C6)cycloalkyl, -{CH2)n-R9, -CO-OR9, -CO-R9, -CON(R7)(R9), -NfR'XR9), -SOR9, -SO2R9 and optionally substituted straight or branched (C,-C8)alkyl chain optionally including -CO-, -COO-, -SO-, -SO2-, -CONH-, -NHCO-, -N- or -O- groups embedded within the alkyl chain; and when Y is O, R3 is not alkyldiazeapane, -C(CH3)2COOCH2CH3 or -CH2CH2N(CH2CH3)2, and when Y is -CH2-, R3 is not -CH2COOH; or Y is a bond and R3 is optionally substituted morpholino; R4 is H, -(C1-C4)alkyl, -O-(C1-C3)alkyl, -CF3, -CN or halo; R5 is H, O-(C1-C3)alkyl or (C1-C3)alkyl; each occurrence of R7 or R7 is independently H or optionally substituted (C1-C3)alkyl; R8 is H, optionally substituted CH3, or -COR9; R9 is hydrogen, optionally substituted (C1-C3)alkyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl or optionally substituted (C3-C6)cycloalkyl; and nis 1,2, 3 or 4; provided that R1 is not optionally substituted furanyl or -C(O)-optionally substituted furanyl; R3 is not optionally substituted quinolinyl; R9 is not optionally substituted cyclopropyl, optionally substituted cyclohexyl, optionally substituted furanyl, optionally substituted imidazolyl, optionally substituted indolyl, optionally substituted naphthyl, optionally substituted piperazinyl, optionally substituted pyrazolyl, optionally substituted pyridazinyl or optionally substituted quinolinyl; R1 is not substituted by -C(O)-cyclopentyl, optionally substituted cyclopentyl, -C(O)-cyclobutyl, cyclobutyl, -C(O)-cyclohexyl or optionally substituted cyclohexyl; R3 is not substituted by -C(O)-cyclopropyl; when R3 is CH3 or 4-chlorophenylmethyl, L-R1 is not cyclopropyl, cyclopentyl, optionally substituted cyclohexyl, -CH2-cyclohexyl, -NH-cycIohexyl, -CH2CH2-cyclohexyl or optionally substituted pyrazolyl; when Y is O, R3 is not -(C0-C4)alkyl-optionally substituted isoxazolyl or optionally substituted pyrazolyl; when L is (C1-C3)alkyl, R1 is not optionally substituted isoxazolyl; when L is a bond, R1 is not optionally substituted cyclobutyl, optionally substituted cyclohexyl, optionally substituted naphthyl, -CH2-optionally substituted naphthyl, -CH2-O-optionally substituted naphthyl, optionally substituted pyrazolyl or tetrahydrobenzofuranyl; the compound is not (Formula Removed) the compound is not (Formula Removed) wherein R3 is optionally substituted piperazinyl or optionally substituted phenyl; the compound is not (Formula Removed) wherein R1 is optionally substituted pyridine or 3-chlorophenyl and -Y-R3 is -NH-C(O)-optionally substituted phenyl; -O-optionally substituted pyridinyl; -NH-C(O)-OCH3; -CH2-optionally substituted piperazinyl; -O-optionally substituted (C1-C9)alky 1; -CH2-morpholinyl; or -O-C(O)-optionally substituted pyridinyl; provided the compound is not (Formula Removed) wherein L is CH2, CH(CH3) or CH2CH2; Y is O or CH2; R2isHorOCH3; R3 is CH3 or OCF3; and RisHorNO2; provided the compound is not (Formula Removed) provided the compound is not (Formula Removed) wherein R1 is phenyl, 4-chIorophenyl, piperidinyl or thienyl. In a fifteenth embodiment the invention provides compounds according to the fourteenth embodiment wherein each substituent or optional substitutent is independently one or more R10 groups wherein R10 is optionally substituted alkyl, alkenyl, optionally substituted alkoxy groups, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylheterocycloalkoxy, alkyl, alkylamino, alkylcarbonyl, alkylester, alkyl-O-C(O)-, alkyl-heterocyclyl, alkyl-cycloalkyl, alkyl-nitrile, alkylsulfonyl, alkynyl, amido groups, amino, aminoalkyl, aminoalkoxy, aminocarbonyl, carbonitrile, carbonylalkoxy, carboxamido, CF3, CN, -C(O)OH, -C(O)H, -C(O)-C(CH3)3, -OH, -C(O)O-alkyl, -C(O)O-cycloalkyl, -C(O)O-heterocyclyl, -C(O)-alkyl, -C(O)2-a]pyrazine-7-carboxylic acid benzyl ester (Formula Removed) To a solution of benzyl 3-methyl-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)-carboxylate (1.085 g, 4.00 mmol) in 1,2-dichloroethane (60ml) was added NIS (4.50 g, 20.00 mmol) and the reaction was heated at reflux for one hour. The reaction was cooled to room temperature and poured into 100ml of saturated 5% sodium thiosulfate solution. The layers were separated and the aqueous layer was re-extracted with 1,2-dichloroethane (40ml). The combined organic layers were washed with water (100 ml), dried over sodium sulfate, filtered and concentrated. Product was extracted from the residue by trituration with 3 X 50ml portions of ether. The extract was filtered and concentrated to yield 2-lodo-3-methyl-5,6-dihydro-8H-imidazo[ 1,2-a]pyrazine-7-carboxylic acid benzyl ester (1.42 g, 89%) as a pale yellow oil. LCMS (Table 1, Method a) R, = 3.32 min, m/z 398.59 (M+H)+'; 1H NMR (400 MHz, CHCl3) δ 7.35 (m, 5H), 5.13 (s, 2H), 4.56 (s.broad, 2H), 4.38 (t, 2H), 3.82 (s, broad, 2H), 2.09 (s, 3H) Preparation #16: 3-Methyl-5,6-dihydro-8H-imidazo[l,2-a]pyrazine-2,7-dicarboxylic acid 7-benzyl ester (Formula Removed) A solution of benzyl 2-iodo-3-methyl-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)-carboxylate (900mg, 2.266 mmol) in dry THF (25 ml) was cooled to 0 °C and ethyl magnesiumbromide (1.888 ml, 5.66 mmol) was added at such a rate as to maintain the reaction temperature below 2.5°C. The reaction was stirred under Nitrogen at 0 °C for 15 minutes, then the reaction was quenched with a stream of carbon dioxide. The reaction was concentrated to solids and acetic acid (0.60 ml, 10.48 mmol) ethyl acetate (50 ml) were added and the suspension was stirred vigorously at room temperature for 15 minutes. The resulting solid was filtered and washed with an additional 15ml ethyl acetate. The residue was dissolved in 10ml water plus 2N HC1 to pH 4, then washed 2 times 10ml ether then extract with 4 X 20ml CH2C12. Dry the combined organic extracts over sodium sulfate, filtered and dried under reduced pressure to yield 3-Methyl-5,6-dihydro-8H-imidazo[l,2-a]pyrazine-2,7-dicarboxylic acid 7-benzyl ester (374 rag, 52%) as a foam. LCMS (Table 1, Method a) R, = 2.28 min, m/z 316.10 (M+H)+; 1H NMR (400 MHz, DMSO-d6) δ 7.35 (m, 5H), 5.11 (s, 2H), 4.56 (s.broad, 2H), 3.88 (m, 2H), 3.83 (s, broad, 2H), 2.36 (s, 3H). Example #27: Preparation of 2-[3-(3-Chloro-4-isopropoxy-phenyl)-[l,2,4]oxadiazol-5-yl)-3-methyI-5,6-dihydro-8H-imidazo[l,2-a]pyrazine-7-carboxylic acid benzyl ester (Formula Removed) To a solution of 7-(benzyloxycarbonyl)-3-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazine-2-carboxylic acid (370mg, 1.173 mmol) in DCM (10ml) was added oxalyl chloride (2.054 ml, 23.47 mmol) and DMF (5 uL). The reaction was stirred for one hour and concentrated. A solution of (E)-3-chloro-N'-hydroxy-4-isopropoxybenzimidamide (268 mg, 1.173 mmol) in pyridine (10.00 ml) was added and the reaction was stirred at room temperature for 30 minutes. The reaction was treated with acetyl chloride (0.092 ml, 1.291 mmol) and then was heated at 115 °C under nitrogen for 4 hours. The reaction was cooled, concentrated and partitioned between saturated Na2CO3 and methylene chloride. The organic layer was washed with water, dried (sodium sulfate), filtered and concentrated under reduced pressure. The residue was purified on silica gel using 80:20 / methylene chloride:ethyl acetate as the eluant toyie.ld2-[3-(3-Chloro-4-isopropoxy-phenyl)-[l,2,4]oxadiazol-5-yl]-3-methyl-5,6-dihydro-8H-imidazo[l,2-a]pyrazine-7-carboxylic acid benzyl ester (173 mg, 29%) as an off-white solid. LCMS (Table 1, Method a) R, = 4.34min, m/z 508.24 (M+H)+; 1H NMR (400MHz, DMSO-d6) δ 7.98 (d, 1H), 7.93 (d,d, 1H), 7.35 (m, 6H), 5.12 (s, 2H), 4.78 (m, 1H), 4.66 (s,broad, 2H), 3.99 (m, 2H), 3.88 (s, broad, 2H), 2.57 (s, 3H), 1.31 (d, 6H). Example #28: Preparation of 2-[3-(3-Chloro-4-isopropoxy-phenyl)-[l,2,4]oxadiazol-5-yl]-3-methyl-5,6,7,8-tetrahydro-imidazo[l,2-a]pyrazine (Formula Removed) A. solution of benzyl 2-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-y!)-3-methyl-5,6-dihydroimidazo[l,2-a]pyrazine-7(8H)-carboxylate (160mg, 0.315 mmol) in 33% HBr solution in acetic acid (2.00 mL) containing triisopropylsilane (0.065 mL, 0.315 mmol)) was stirred at room temperature under nitrogen for 10 minutes. Ether (20 ml) was added to precipitate the product. The resulting solid was filtered off, treated with saturated bicarbonate solution (10 ml) and extracted with methylene chloride (2 X 10 ml). The combined organic layers were dried over sodium sulfate, filtered, concentrated to solids and dried under reduced pressure to yield 2-[3-(3-Chloro-4-isopropoxy-phenyl)-[l,2,4]oxadiazol-5-yl]-3-methyl-5,6,7,8-tetrahydro-imidazo[l,2-ajpyrazine (113 mg, 96 %) as an off-white solid. LCMS (Table 1, Method a)R, = 3.14 min, m/z 374.24 (M+H)+; 'HNMR (400MHz, DMSO-d6) δ 8.01 (d, 1H), 7.97 (d,d, 1H), 7.36 (d, 1H), 4.81 (m, 1H), 4.66 (s, 2H), 3.90 (s, 2H), 3.87 (t, 2H), 3.12 (t, 2H), 2.60 (s, 3H), 1.34 (d, 6H). Example #29: Preparation of l-{2-[3-(3-Chloro-4-isopropoxy-phenyl)-[l,2,4]oxadiazol-5-yl]-3-methyl-5,6-dihydro-8H-itnidazo[l,2-a]pyrazin-7-yl}-ethanone (Formula Removed) To a solution of 2-(3-chloro-4-isopropoxyphenyl)-3-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazine (32mg, 0.105 mmol) in methlyene chloride (2.0 ml) was added acetyl chloride (7.50 uL, 0.105 mmol) at room temperature. The mixture was stirred at room temperature for 4 hours and concentrated. The residue was purified by reverse phase HPLC to yield l-{2-[3-(3-Chloro-4-isopropoxy-phenyl)-[l,2,4]oxadiazol-5-yl]-3-methyl-5.6-dihydro-8H-imidazo[l,2-a]pyrazin-7-yl}-ethanone (31 mg, 86%) as an off-white solid. LCMS (Table 1, Method a) R, = 3.46 min, m/z 416.20(M+H)+; 1H NMR (400 MHz, DMSO-d6) δ 8.02 (d, 1H), 8.97 (d,d, 1H), 7.37 (d, 1H), 4.81 (m, 2H), 4.70 (s, 2H), 3.90 (s, 2H), 4.07 (t0m, 1H), 3.95 (m, 3H), 2.62 (s, 3H), 2.14 (m, 3H), 1.34 (d, 6H). Example #30: Preparation of {2-[3-(3-Chloro-4-isopropoxy-phenyl)-[l,2,4]oxadiazol-5-yl]-3-methyl-5,6-dihydro-8H-irnidazo[l,2-a]pyrazin-7-yl}-acetic acid tert-butyl ester (Formula Removed) To a solution of 3-(3-chloro-4-isopropoxyphenyl)-5-(3-methyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyrazin-2-yl)-l,2,4-oxadiazole (50.0mg, 0.134 mmol) in DMF (1.0ml) at room temperature was added sodium carbonate (28.4 mg, 0.267 mmol) and tert-butyl bromoacetate (0.021 ml, 0.140 mmol) at room temperature. The reaction was continued overnight. The reaction was filtered and concentrated. The residue was dissolved in ethyl acetate (10 ml), washed with brine (10 ml), dried over sodium sulphate, filtered and concentrated to yield (2-[3-(3-Chloro-4-isopropoxy-phenyl)-[l,2,4]oxadiazol-5-yl]-3-methyl-5,6-dihydro-8H-imidazo[l,2-aJpyrazin-7-yl] -acetic acid tert-butyl ester (35 mg, 54%) as an off-white foam which was used in the next step without further purification. LCMS (Table 1, Method a) R, = 4.32 min, m/z 488.29 (M+H)+ Example #31: Preparation of {2-[3-(3-Chiloro-4-isopropoxy-phenyl)-[l,2,4]oxadiazol-5-yl)-3-methyI-5,6-dihydro-8H-imidazo[l,2-a]pyrazin-7-yl}-acetic acid, triflouroacetic acid salt (Formula Removed) To a solution of tert-butyl 2-(2-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)-3-methyl-5,6-dihydroimidazo[l,2-a]pyrazin-7(8H)-yl)acetate (32rag, 0.066 mmol) and Triisopropylsilane (0.013 ml, 0.066 mmol) in methylene chloride (2.o ml) was added TFA (2.0 ml) at room temperature for 3 hours. The reaction was diluted with ether (20 ml) and the product was filtered off and dried under reduced pressure. LCMS (Table 1, Method a) R, = 2.99min,m/z432.23 (M+H)+; 1H NMR(400MHz,DMSO-d6)88.0(m, 2H), 7.36 (m, 1H), 4.81 (m, 1H), 3.97 (m, 2H), 3.84 (m, 2H), 3.46 (m, 2H), 3.09 (m, 2H), 2.59 (s, 3H), 1.33 (d, 6H). Preparation #17: 2-Methyl-imidazo[l,2-a]pyrazme-3-carboxylic acid ethyl ester (Formula Removed) A solution of pyrazin-2-amine (3.6 g, 37.9 mmol) and ethyl 2-chloro-3-oxobutanoate (5.24 ml, 37.9 mmol) in ethanol (30 ml) was heated at reflux for 9 hours. A IN solution of HC1 in ether was added and the mixture was concentrated under reduced pressure. The residue was triturated with 3 X 50ml acetonitrile and filtered to yield crude 2-Methyl-imidazo[l,2-a]pyrazine-3-carboxylic acid ethyl ester (4.5 g, 58%) as an amorphous solid which was used in the next step without further purification. Preparation #18: 2-Methyl-imidazo[l,2-a]pyrazuie-3-carboxylic acid (Formula Removed) A solution of sodium hydroxide (1.754 g, 43.9 mmol) in water (25 ml) was added to crude ethyl 2-methylimidazo[l,2-a]pyrazine-3-carboxylate (4.5g, 21.93 mmol). The reaction is exothermic and goes to completion in minutes without additional heating. The mixture was acidified with concentrated HCI to pH 5. The solution was injected onto a preparative C18 column and washed with water and then eluted with 20% CH3CN / water. The product fractions were combined and concentrate to yield 2-Methyl-imidazo[l,2-a]pyrazine-3-carboxylic acid (250mg, 6%) as a tan solid. LCMS (Table 1, Method a) R, = 0.84 min, m/z 176.18 (M-H)-; 1H NMR (400 MHz, DMSO-d6) δ 9.12 (m, 2H), 8.12 (m, 1H), 2.66 (s, 3H). Example #32: Preparation of 3-[3-(3-Chloro-4-isopropoxy-phenyl)-[l,2,4]oxadiazol-5-yl]-2-methyl-imidazo[l ,2-a]py razine (Formula Removed) A solution of 2-methylimidazo[l,2-a]pyrazine-3-carboxylic acid (250mg, 1.411 mmol) in DCE (5 ml) was treated with Hunig's Base (0.542 ml, 3.10 mmol) and HATU (590 mg, 1.552 mmol) at room temperature for 15 minutes and 40C for 30min. The reaction was concentrated and the residue was dissolved in acetic acid (10 ml) and heated at 100°C for 45 minutes. The reaction was cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between saturated sodium carbonate solution (10 ml) and methylene chloride (2 X 10 ml). The organic layers were dried with sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified on silica gel using 9:17 CH2Cl2:MeOH. The product fractions were combined and concentrated under reduced pressure to yield 3-[3-(3-Chloro-4-isopropoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-2-methyl-imidazo[1,2-a]pyrazine (133 mg, 25%) as a tan solid. LCMS (Table 1, Method a) R, = 4.31 min, m/z 370.25 (M+H)+; 1H NMR (400 MHz, DMSO-d6) δ 9.43 (d,d, 1H), 9.26 (d, 1H), 8.30 (d, 1H), 8.21 (d, 1H), 8.10 (d,d, 1H), 7.40 (d, 1H), 4.84 (m, 1H), 2.84 (s, 3H), 1.36 (d, 6H) Example #33: Preparation of 3-(3-chloro-4-isopropoxyphenyl)-5-(4-((2,2-dimethyl-l,3-dioxolan-4-yl)methoxy)phenyl)-l,2,4-oxadiazole (Formula Removed) In a 25 mL microwave tube 4-((2,2-dimethyl-l,3-dioxolan-4-yl)methoxy)benzoyl chloride (0.483 g, 1.784 mmol) and (Z)-3-chloro-N'-hydroxy-4-isopropoxybenzimidamide (0.272 g, 1.189 mmol) in pyridine (15mL) were combined to give an orange solution. The vessel was capped and the reaction heated at 200°C for 20 min under microwave irradiation (Biotage Optimizer, 300 W). The mixture was cooled , the solvent was removed to afford a yellow solid, which was partitioned between water (100 mL) and EtOAc (50 mL), extracted by EtOAc (2x30 mL), the combined EtOAC layer was washed by water (2x30 mL), and concentrated to afford a yellow solid, which was purified via silica gel chromatography (40 g, 30% EtOAc:Heptane) to afford 3-(3-chloro-4-isopropoxyphenyl)-5-(4-((2,2-dimethyl-l,3-dioxolan-4-yl)methoxy)phenyl)-l,2,4-oxadiazole (0.3g, 0.674 mmol, 56.7 % yield) as white solid. LC/MS (30_95 NH4OAc 4m GC8.olp) R, = 3.22 min.; MS m/Z: 445.31 (M+H)+. 1H NMR (400 MHz, Solvent d-DMSOδ ppm 8.17-8.09 (m, 2H), 8.05 (d, J = 2.13 Hz, 1H), 7.99 (dd, J = 8.64, 2.15 Hz, 1H), 7.38 (d, J = 9.01 Hz, 1H), 7.26-7.19 (m, 2H), 4.88-4.77 (m, 1H), 4.45 (s, 1H), 4.23-4.07 (m, 3H), 3.79 (dd, 7 = 8.42,6.29 Hz, 1H), 1.35 (m, 12H). Preparation #19: tert-butyl 2-(4-(chlorocarbonyl)phenoxy)acetate (Formula Removed) In a 100 mL round bottomed flask was 4-(2-tert-butoxy-2-oxoethoxy)benzoic acid (0.76 g, 3.01 mmol) in Dichloromethane (30.1 ml) to give a colorless suspension. Five drops DMF was added to the solution. The reaction mixture was cooled by ice-bath. Oxalyl chloride (0.396 ml, 4.52 mmol) was added dropwise. The ice-bath was removed, and the solution was stirred at room temperature for 40 min. The reaction mxiture was concentrated to afford ten-butyl 2-(4-(chlorocarbonyl)phenoxy)acetate (0.86 g, 3.18 mmol, 105 % yield) as colorless oil. 1H NMR (400 MHz, CDCl3) d ppm 8.10 (d, 2H), 6.95 (d, 2H), 4.61 (s, 2H), 1.49 (s, 9H) Example #34: Preparation of 2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenoxy)acetic acid (Formula Removed) A 25 mL microwave reaction vial was charged with tert-butyl 2-(4-(chlorocarbonyl)phenoxy)acetate (0.815 g, 3.01 mmol) and pyridine (15 mL), (Z)-3-chloro-N'-hydroxy-4-isopropoxybenzimidamide (0.459 g, 2.007 mmol) was added. The vessel was capped and the reaction heated at 200°C for 20 min under microwave irradiation (Biotage Optimizer, 300 W). The mixture was cooled, the reaction mixture was poured into stirring HC1 (10%, 100 mL), the resulting suspension was filtered, the solid was washed by HC1 (5%, 2x10 mL) and dried to afford grey solid, which was purified by RP-HPLC (A = 50mM ammonium acetate, B = acetonitrile; 30-95% B over 25.0 min (21.0 mL/min flow rate); 21.2 x 250 mm Thermo Hyperprep C18 column, 8 um particles) to give 2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenoxy)acetic acid (0.246 g, 0.633 mmol, 31.5 % yield) as white solid. LC/MS (Table 1, Method f) R, = 2.08 min.; MS m/z: 389.14 (M+H)+. 1H NMR (400 MHz, Solvent d-DMSOδ ppm 13.28-13.07 (m, 1H), 8.13 (d, J = 9.03 Hz, 2H), 8.05 (d, J = 2.13 Hz, 1H), 7.99 (dd, J = 8.64, 2.15 Hz, 1H), 7.38 (d, J = 9.04 Hz, 1H), 7.18 (d, 7 = 9.06 Hz, 2H), 4.85 (s, 3H), 1.35 (d, J = 6.03 Hz, 6H). Example #35: Preparation of 5-(6-(lH-benzotd][l^]triazol-l-yloxy)pyridin-3-yl)-3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazole (Formula Removed) A 25 mL microwave reaction vial was charged with (Z)-3-chloro-N'-hydroxy-4-isopropoxybenzimidamide (0.1 g, 0.437 mmol), 6-bromonicotinic acid (0.097 g, 0.481 mmol), and DCC (0.099 g, 0.481 mmol) in acetonitrile (2.403 ml). HOBT (0.074 g, 0.481 mmol) was added in one portion, the resulting suspension was allowed to stir at room temperature for 10 min. DIEA (0.168 ml, 0.962 mmol) was added dropwise, the reaction mixture was heated at 120°C for 30 min under microwave irradiation (Biotage Optimizer, 300 W). The solution was cooled, the reaction mixture was partitioned between EtOAc (50 mL) and water (50 mL), the organic layer was washed by water (2x50 mL), and concentrated afforded yellow solid, which was purified via silica gel chromatography (12 g, 20% EtOAc:Heptane) to afford 5-(6-(1 H-benzo[d] [ 1,2,3]triazol-1 -y loxy)pyridin-3-y l)-3-(3-chloro-4-isopropoxypheny 1)-1,2,4-oxadiazole (0.128 g, 0.285 mmol, 65.2 % yield) as a white solid. LC/MS (Table 1, Method a) R, = 3.74 min.; MS m/z: 449.18 (M+H)+. 1H NMR (400 MHz, Solvent d-DMSO) ppm 8.88 (dd, J = 2.25,0.65 Hz, 1H), 8.62 (dd, J = 8.68, 2.27 Hz, 1H), 8.15 (t, J = 5.28 Hz, 2H), 7.97 (dd, 7 = 8.62, 2.14 Hz, 1H), 7.55 (d, 7 = 0.96 Hz, 1H), 7.52-7.44 (m, 2H), 7.36 (dd, 7 = 8.68, 0.70 Hz, 1H), 7.03 (d, 7 = 8.87 Hz, 1H), 4.73-4.61 (m, 1H), 1.46-1.40 (m, 6H). Preparation #20: (Z)-3-bromo-N'-hydroxy-4-isopropoxybenzimidamide (Formula Removed) 3-bromo-4-isopropoxybenzonitrile (0.68g, 2.83 mmol) and hydroxylamine (0.208 mJ, 3.12 mmol) were combined in EtOH (20 ml). The reaction mixture was heated at 65 °C for 16 hr. The reaction mixture was concentrated to afford (Z)-3-bromo-N'-hydroxy-4-isopropoxybenzimidamide (0.76 g, 2.78 mmol, 98 % yield) as pale yellow solid. LC/MS (Table 1, Method a) R, = 2.89 min.; MS m/z: 275.00 (M+H)+. Example #36: Preparation of 4-(3-(3-bromo-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzonitrile (Formula Removed) A 25 mL microwave vial equipped with a stirring bar was charged with 4-cyanobenzoyl chloride (0.4 g, 2.416 mmol), (Z)-3-bromo-N'-hydroxy-4-isopropoxybenzimidamide (0.5 g, 1.831 mmol) and pyridine (15 ml) to give an orange solution. The vessel was capped and the reaction heated at 200°C for 20 min under microwave irradiation (Biotage Optimizer, 300 W). The solution was cooled, the reaction mixture was partitioned between aqueous HC1 (10%, 150 mL) and DCM (40 mL) mixture, the DCM layer was drained, and the aqueous layer was extracted by DCM (2x20 mL). The combined DCM layers were washed by water (2x20 mL) and concentrated to afford white solid, which was purified via silica gel chromatography (40 g, 40% EtOAcHeptane) to afford 4-(3-(3-bromo-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzonitrile (0.638 g, 1.660 mmol, 91 % yield) as white solid. LC/MS (Method c) R, = 3.17 min.; MS m/z: 386.19 (M+H)+. 1H NMR (400 MHz, Solvent d-DMSO) ppm 8.40-8.32 (m, 2H), 8.23 (d, J = 2.13 Hz, 1H), 8.14 (dd, J = 8.14, 0.61 Hz, 2H), 8.05 (dd, J = 8.65, 2.15 Hz, 1H), 7.36 (d, J = 9.12 Hz, 1H), 4.89-4.77 (m, 1H), 1.35 (d, J = 6.03 Hz, 6H). Example #37: Preparation of 4-(3-(3-bromo-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzaldehyde (Formula Removed) A 100 mL round-bottomed flask equipped with septa cap outfitted with nitrogen inlet needle was charged with 4-(3-(3-bromo-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzonitrile (0.64 g, 1.666 mmol) in DCM (33.3 ml) to give a colorless solution. The reaction mixture was cooled to -40 °C by acetonitrile-dry ice bath and it turned into a white suspension. Dibal-H (3.33 ml, 3.33 mmol) was added dropwise over 10min. It was stirred for extra 60 min at -40 °C. Methanol (0.135 ml, 3.33 mmol) was added dropwise to quench the reaction. Then all of the mixture was poured into stirring Rochelle's salt (200 mL). It was stirred at room temperature for 4 hr, then it was partitioned, the aqueous layer was extracted by DCM (2x50 mL), the combined DCM layers were washed by water (60 mL), dried over MgSO4. Filtration and concentration afforded 1.04 g orange oil, which was purified via silica gel chromatography (40 g, 40% EtOAcHeptane) to afford 4-(3-(3-bromo-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzaldehyde (0.551 g, 1.423 mmol, 85 % yield) as pale yellow solid. LC/MS (Method c) R, = 3.17 min.; MS m/z: 388.94 (M+H)+. 1H NMR (400 MHz, Solvent d-DMSO) ppm 10.15 (s, 1H), 8.41 (d, J = 8.20 Hz, 2H), 8.24 (d, J = 2.13 Hz, 1H), 8.20-8.14 (m, 2H), 8.06 (dd, J = 8.64, 2.15 Hz, 1H), 7.37 (d, J = 9.11 Hz, 1H), 4.89-4.78 (m, 1H), 1.36 (d, J = 6.03 Hz, 6H). Example #38: Preparation of 3-(3-bromo-4-isopropoxyphenyl)-5-(4-(dimethoxymethyl)phenyI)-l,2,4-oxadiazoIe (Formula Removed) 4-(3-(3-bromo-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzaldehyde (0.551 g, 1.423 mmol), molecular sieve (4A, 8-12 mesh, 130 mg) and p-toluenesulfonic acid monohydrate (0.037 g, 0.195 mmol) were added in trimethyl orthoformate (4 ml, 36.2 mmol) and methanol (6 ml), the reaction mixture was heated at 80 °C for 16 hr. The solution was cooled, the reaction mixture was concentrated to afford grey solid, which was purified via silica gel chromatography (12 g, 20% EtOAcHeptane) to afford 3-(3-bromo-4-isopropoxyphenyl)-5-(4-(dimethoxymethyl)phenyl)-l,2,4-oxadiazole (0.61 g, 1.366 mmol, 96 % yield) as white solid. LC/MS (Table 1, Method a) R, = 3.31 min.; MS m/z: 435.03 (M+H)+. 1H NMR (400 MHz, Solvent d-DMSO) ppm 8.25-8.19 (m, 3H), 8.05 (dd, J = 8.63, 2.14 Hz, 1H), 7.67 (d, J = 8.18 Hz, 2H), 7.35 (d, J = 9.02 Hz, 1H), 5.52 (s, 1H), 4.86-4.78 (m, 1H), 3.30 (s, 6H), 1.35 (d, J = 6.02 Hz, 7H). Example #39: Preparation of 5-(5-(4-(dimethoxvmethyl)phenyl)-l,2,4-oxadiazol-3-yl)-2-isopropoxybenzonitrile (Formula Removed) A 25 mL microwave vial equipped with a stirring bar was charged with 3-(3-bromo-4-isopropoxyphenyl)-5-(4-(dimethoxymethyl)phenyl)-l,2,4-oxadiazole (0.25g, 0.577 mmol), copper(I) cyanide (0.133 g, 1.485 mmol) and pyridine (15 ml). The vessel was capped and the reaction heated to 230°C for 30 min under microwave irradiation (Biotage Optimizer, 300 W). The solution was cooled, the reaction mixture was concentrated, to the residue was added hydrated ferric chloride (0.8 g), concentrated hydrochloric acid (2 mL) and water (12 mL). The solution was heated at 65 °C for 20 min, the aqueous mixture was extracted by DCM (3X30 mL), the combined DCM layers were washed with FeCh solution (2x20 mL), then water (2x20 mL), dried (brine, MgSO4) and concentrated to yield yellow solid, which was purified via silica gel chromatography (40 g, 20% EtOAc:Heptane) to afford 5-(5-(4-(dimethoxymethyl)phenyl)-l,2,4-oxadiazol-3-yl)-2-isopropoxybenzonitrile (0.086 g, 0.227 mmol, 39.3 % yield) as pale yellow solid. Example #40: Preparation of 5-(5-(4-formylphenyl)-l,2,4-oxadiazol-3-yl)-2-isopropoxybenzonitrile (Formula Removed) 5-(5-(4-(dimethoxymethyl)phenyl)-l,2,4-oxadiazol-3-yl)-2-isopropoxybenzonitrile (0.086 g, 0.227 mmol) and p-toluenesulfonic acid monohydrate (0.043 g, 0.227 mmol) were added in acetone (10 ml) to give a colorless solution. The reaction mixture was heated at 60 °C for 2 hr. The solution was cooled, the reaction mixture was concentrated, the residue was purified via silica gel chromatography (12 g, 50% EtOAcrHeptane) to afford 5-(5-(4-formylphenyl)-l,2,4- oxadiazol-3-yl)-2-isopropoxybenzonitrile (0.077 g, 0.231 mmol, 102 % yield) as white solid. LC/MS (Table 1, Method f) R, = 2.88 min.; MS m/z: 334.08 (M+H)+. Example #41: Preparation of l-(4-(3-(3-cyano-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzyl)azetidine-3-carboxylic acid (Formula Removed) 5-(5-(4-formylphenyl)-l,2,4-oxadiazol-3-yI)-2-isopropoxybenzonitrile (0.077 g, 0.231 mmol) and azetidine-3-carboxylic acid (0.028 g, 0.277 mmol) were combined in methanol (11.55 ml) and DCE (11.55 ml) in a sealed vial. Acetic acid (0.066 ml, 1.155 mmol) was added. The reaction mixture was stirred at ambient temperature for 2 hr. MP-cyanoborohydride (0.265 g, 0.570 mmol) was added and the reaction stirred for about 24 h. The solution was filtered, the solid was washed with methylene chloride and methanol, and the filtrate was concentrated to afford a white solid, which was recrystalized by methanol (5 mL) to give l-(4-(3-(3-cyano-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzyl)azetidine-3-carboxylic acid (0.025 g, 0.060 mmol, 25.9 % yield) as white solid: LCMS (Table 1, Method a) R, = 2.10 min.; MS m/z: 420.26 (M+H)+. 1H NMR (400 MHz, Solvent d-DMSO) ppm 8.35-8.28 (m, 2H), 8.17-8.11 (d, J = 8.00 Hz, 2H), 7.56-7.50 (m, 8.69 Hz, 3H), 4.98-4.89 (m, 1H), 3.68 (s, 2H), 3.43 (s, 2H), 3.25-3.23 (m, 3H), 1.38 (d, J = 6.03 Hz, 6H). Example #42: Preparation of l-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)cyclopropanecarbonitrile (Formula Removed) A 20mL microwave vial was charged with 4-(l-cyanocyclopropyl)benzoic acid (720mg, 3.85 mmol), (Z)-3-chloro-N'-hydroxy-4-isopropoxybenzimidamide (880 mg, 3.85 mmol), DCC (873 mg, 4.23 mmol), HOBT (648 mg, 4.23 mmol), ACN (10 ml), and DIEA (1.478 ml, 8.46 mmol). The vial was capped and heated to 160 °C via microwave irradiation for 25 minutes (max 300W). Solvent was removed under reduced pressure and crude oil was purified by flash column chromatography (Analogix system, heptane/ethyl acetate, 0- 45%ethyl acetate over 30min; 80g column, 60 mL/min flow rate). Fractions containing product were combined, rotovapped, and dried in a vacuum oven overnight to give ]-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)cyclopropanecarbonitrile (347 mg, 23.8%) as a yellow solid. LCMS (Table 1, Method c) R, = 3.19 min, m/z 380.43 (M+H)+; 1H NMR (400 MHz, DMSO)) δ ppm 8.22-8.12 (m, 2H), 8.05 (d, 1H), 7.99 (dd, 2.14 Hz, 1H), 7.62-7.55 (m, 2H), 7.38 (d, 1H), 4.82 (td, 1H), 1.90 (q, 2H), 1.67 (q, 2H), 1.38-1.33 (m, 6H). Example #43: Preparation of l-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)cyclopropanecarbaldehyde (Formula Removed) A 100 mL round bottom flask was charged with l-(4-(3-(3-chloro-4-isopropoxyphenyl)-1,2,4-oxadiazol-5-yl)phenyl)cyclopropanecarbonitrile (300mg, 0.790 mmol) and Dichloromethane (8 mL) and then cooled to -40°C. DIBAL-H (0.869 mL, 0.869 mmol) was added slowly via syringe and the reaction mixture left to warm to room temperature overnight. Reaction quenched by addition of MeOH (4mL), and aqueous Rochelle's salt (4 mL). Layers were separated and the aqueous layer was extracted with DCM (3x 25mL). Organics were washed with saturated sodium bicarbonate solution, then dried over MgSO4, and concentrated. To a solution of the crude material in 3mL of THF was added 3mL of IN HC1. The mixture was stirred at room temperature for Ihr. Mixture was rotovapped to remove THF. Material was then purified via flash column chromatography (Analogix, 40g column, 0-40% ethyl acetate in heptane over 30min, 30 ml/min flow rate). Fractions containing product were combined and concentrated to give l-(4-(3-(3-Moro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)cyclopropanecarbaldehyde (144 mg, 48%) as a tacky yellow solid. LCMS (Table 1, Method c) R, = 3.11 min, m/z 383.50 (M+H)+. Example #44: Preparation of 3-((l-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-S-yl)phenyl)cycIopropyl)methylamino)propanoic acid, Trifluoroacetic Acid (Formula Removed) A 20mL vial was charged with l-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)cyclopropanecarbaldehyde (46 mg, 0.120 mmol), methanol (2.5 ml), 3-aminopropanoic acid (10.70 mg, 0.120 mmol) and acetic acid (0.034 ml, 0.601 mmol). The vial was capped and the mixture stirred for about 30 min at room temperature. Next, sodium cyanoborohydride (7.55 mg, 0.120 mmol) was added in one aliquot and the reaction was stirred overnight at room temperature. Solvents were removed under reduced pressure and the crude material was purified via RP-HPLC ( A = 0.1% TFA, B = ACN; 30% to 95% B over 30 min at 21.0 mL/min; UV  = 254 nm; Thermo Hyperprep HS C18,8 µm, 250 x 21.2 mm column). Fractions containing product were, rotovapped, and lyophilized to give 3-((l-(4-(3-(3-chloro-4-isopropoxyphenyl)-I,2,4-oxadiazol-5- yl)phenyl)cyclopropyl)methylamino)propanoic acid (27 mg, 40%) as the TFA salt. LCMS (Table 1, Method c) R, = 2.07 min, m/z 456.25 (M+H)+; 1H NMR (400 MHz, methanol) δ ppm 8.22 (d, 2H), 8.11 (d, 1H), 8.03 (dd, 1H), 7.69 (d, J = 8.19 Hz, 2H), 7.24 (d, 1H), 4.80-4.76 (m, 1H), 3.36 (s, 2H), 3.13 (t,, 2H), 2.44 (t, 2H), 1.40 (d, 6H), 1.17 (d, 4H). Example #45: Preparation N-(4-(3-(3-chloro-4-isopropoxyphenyI)-l,2,4-oxadiazol-5-yl)benzyl)-l-(2,2-dimethyl-l,3-dioxoIan-4-yl)methanamine (Formula Removed) 4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzaldehyde (150 mg, 0.438 mmol), (2,2-dimethyl-l,3-dioxolan-4-yl)methanamine (0.057 mL, 0.438 mmol), methanol (4 mL), and acetic acid (0.125 mL, 2.188 mmol) were loaded into a 25mL flask equipped with a stirring bar. The mixture was stirred for about 10 minutes at room temperature under nitrogen. Sodium cyanoborohydride (27.5 mg, 0.438 mmol) was added in one portion, and the reaction mixture was stirred at room temperature overnight. Solvent was removed under reduced pressure and crude material was purified by RP-HPLC (A = 50 mM ammonium acetate, B = ACN; 40% to 80% B over 30 min at 21.0 mL/min; UV  = 254 nm; Thermo Hyperprep HS C18, 8 nm, 250 x 21.2 mm column). Fractions containing product were combined, rotovapped and lyophilized to give N-(4-(3-(3-chloro-4-isopropoxyphenyl)-1,2,4-oxadiazol-5-yl)benzyl)-1-(2,2-dimethyl-],3-dioxolan-4-yl)methanamine (130.9mg, 64.7%) as a white solid. LCMS (Table 1, Method c) R, = 2.59 min, m/z 458.62 (M+H)+; 1H NMR (400 MHz, DMSO) δ ppm 8.13 (d, 2H), 8.06 (d, 1H), 8.00 (dd, 1H), 7.61 (d, 2H), 7.39 (d, 1H), 4.82 (sept, 1H), 4.15 (p, 1H), 3.99 (dd, 1H), 3.84 (s, 2H), 3.63 (dd, 1H), 2.61 (ddd, 2H), 1.86 (s, 4H), 1.35 (d, 6H) 1.26 (s, 3H). Example #46: Preparation 3-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzylamino)propane-l,2-diol (Formula Removed) To a solution of N-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzyl)-l-(2,2-dimethyl-l,3-dioxolan-4-yl)methanamine (108 mg, 0.236 mmol) in THF (4 mL) was added IN aqueous HC1 (0.778 mL, 0.778 mmol) The reaction was heated to 65°C under nitrogen for 90 minutes. Heating was stopped and the reaction was neutralized by addition of IN aqueous NaOH (0.778 mL, 0.778 mmol). THF was removed under reduced pressure and the remaining aqueous solution was basified (pH approx 9) by the addition of 0.1 N NaOH, at which point white precipitate formed. Solid was collected by vacuum filtration, and washed with 0.1N NaOH (3 x 10mL). Solid was dried in a vacuum oven overnight to give 3-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzylamino)propane-l,2-diol(3l.lmg, 32%) as an off-white solid. LCMS (Table 1, Method c) R, = 1.90 min, m/z 418.47 (M+H)+; 1H NMR (400 MHz, methanol) δ ppm 7.22 (d, J = 8.68 Hz, 1H), 7.60 (d, 2H), 8.01 (dd,, 1H), 8.10 (d, 1H), 8.16 (d, 2H), 4.78 (sept, 1H), 2.76 (dd, 1H), 2.63 (dd, 1H), 3.52 (d, 2H), 3.90 (d, 2H), 3.78 (m, 1H), 1.40 (d, 6H). Example #47: Preparation of (Z)-methyl 3-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)acrylate (Formula Removed) A two-neck round bottom flask was charged with methyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate (0.235 ml, 1.109 mmol), 18-crown-6 (1465 mg, 5.54 mmol) and THF (15 ml). The mixture was then cooled to -78°C under an atmosphere of nitrogen. Potassium bis(trimethylsilyl)amide (221 mg, 1.109 mmol) was added and the mixture stirred for a few minutes. 4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzaldehyde (380 mg, 1.109 mmol) was added and the mixture stirred at -78°C for 90 minutes and then left to warm to room temperature overnight. Reaction was quenched by the addition of saturated NH Cl (aqueous). The mixture was separated and the aqueous layer was extracted with ether (3 x 10mL). The combined organics were dried over MgSO and concentrated to give an off-white solid. Thesolid was triturated with MeOH and collected by vacuum filtration and washed with MeOH (3 x 10 mL). Collected solid was dried overnight in a vacuum oven to give (Z)-methyl 3-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)acrylate (325 mg, 73.5%). LCMS (Table 1, Method c) R, = 3.22 min, m/z 399.16 (M+H)+. 1H NMR (400 MHz, DMSO) δppm8.18(d,2H),8.06(d, 1H), 8.01 (dd, 1H), 7.79(d, 2H),7.40(d, !H),7.18(d, 1H), 6.84 (d, 1H), 6.20 (d, 1H), 4.83 (sept, 1H), 3.67 (s, 3H), 1.35 (d, 6H). Example #48: Preparation of Trans-methyl 2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)cyclopropanecarboxylate (Formula Removed) To a stirred suspension of trimethyIsulfoxonium iodide (234 mg, 1.065 mmol) in DMSO (5.0 mL) under nitrogen, was added, in portions NaH (42.6 mg, 1.065 mmol), with a water bath in place to keep the reaction between 25-30°C. Upon completion of hydrogen evolution, a solution of (Z)-methyl 3-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)acrylate (386mg, 0.968 mmol) in DMSO (5.00 mL) was added drop-wise, keeping the reaction temperature at or below 35°C. After addition was complete, the reaction was stirred at room temperature for an hour and a half and then warmed to 50°C for two hours. 50ml of water was then added to the reaction, and the reaction left to stir at room temperature overnight. The reaction mixture was diluted with saturated aqueous sodium chloride, and the aqueous layer was extracted 3x with 75mL EtOAc. Organic layers were combined, dried over MgSO4, and concentrated. The crude material was purified by RP-HPLC (A = 50 mM ammonium acetate, B = ACN; 30% to 100% B over 30 min at 21.0 mL/min; UV  = 254 nm; Thermo Hyperprep HS C18, 8 µm, 250 x 21.2 mm column). Fractions containing product were combined, concentrated and lyophilized to give Trans-methyl 2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)cyclopropanecarboxylate (155 mg, 39%) as a white solid. LCMS (Table 1, Method c) R, = 3.27 min, m/z 413.17 (M+H)+. 1H NMR (400 MHz, DMSO) δ ppm 8.08 (d, 2H), 8.06 (d, 1H), 7.99 (dd, 1H), 7.47 (d, 2H), 7.39 (d, 1H), 4.82 (sept, 1H), 3.66 (s, 3H), 2.59 (ddd, 1H), 2.12 (ddd, 1H), 1.58 (ddd, 1H), 1.53 (ddd, 1H), 1.35 (d, 6H). Example #49: Preparation of Trans-2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)cycIopropanecarboxylicacid (Formula Removed) To a suspension of (lS,2S)-methyl 2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)cyclopropanecarboxylate (11 Img, 0.269 mmol) in ethanol (5 ml) was added 2 N NaOH (5ml, 10.00 mmol). The mixture was stirred under nitrogen at room temperature overnight. Reaction mixture was neutralized by addition of acetic acid, and then acidified with a few drops of 1 N aqueous HC1 (pH about 2). White solid precipitated and was collected by filtration, washed with 0.1N HCL (3 x 5 mL), and dried under vacuum to give Trans-2-(4-(3-(3-chhro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5- yl)phenyl)cydopropanecarboxylic acid (64 mg, 59%). LCMS (Table 1, Method 0 Rt = 2.99 min, m/z 399.16 (M+H)+. 1H NMR (400 MHz, DMSO) δ ppm 8.07 (d, 2H), 8.05 (d, 1H), 7.99 (dd, 1H), 7.45 (d, 2H), 7.38 (d, 1H), 4.82 (sept., 1H), 2.54 (m, 1H), 1.97 (m, 1H), 1.53 (td, 1H), 1.46 (ddd, 1H), 1.35 (d, 6H). Example #50: Preparation of tert-butyl 5-(3-(3-chIoro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)isoindoline-2-carboxylate (Formula Removed) To a solution of 2-(tert-butoxycarbonyl)isoindoline-5-carboxylic acid (190 mg, 0.722 mmol) in acetonitrile (3 mL) in a 5 mL microwave vial was added HOBT (330 mg, 2.16 mmol), DCC (298 mg, 2.16 mmol), and DEA (0.115 mL, 0.656 mmol). The mixture was stirred at room temperature for approximately 16 hours. Next, (Z)-3-chloro-N'-hydroxy-4-isopropoxybenzimidamide (150 mg, 0.656 mmol) (prepared by General procedure B) was added and the reaction was heated to 150 ° C under microwave irradiation (max 300W) for 20 minutes. After cooling, the reaction mixture was filtered, concentrated, and purified via Analogix system using RediSep 40g column, with a gradient of 0-40% EtOAc/Heptane over 30 min. at a flow rate of 30ml/min. Fractions containing product were combined, rotovapped, and dried in a vacuum oven to give ten-butyl 5-(3-(3-chloro-4-isopropoxyphenyl)-1.2,4-oxadiazol-5-yl)isoindoline-2-carboxylate (46.2 mg, 15.5%) LCMS (Table 1, Method c) R, = 3.40 min, m/z 456.22 (M+H)+; 1H NMR (400 MHz, DMSO) δ ppm 8.16 (d, 1H), 8.10 (s, 1H), 8.05 (d, 1H), 7.61 (m, 1H), 7.39 (d, 1H), 4.82 (sept, 1H), 4.70 (d, 4H), 1.48 (s, 9H), 1.35 (d, 6H). Example #51: Preparation of 3-(3-chloro-4-isopropoxyphenyl)-5-(isoindolin-5-yl)-l,2,4-oxadiazole, Trifluoroacetic Acid (Formula Removed) To a solution of tert-butyl 5-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)isoindoline-2-carboxylate (41mg, 0.090 mmol) in DCM (2 ml) was added TFA (0.5 mL, 6.49 mmol). The mixture was stirred at room temperature under nitrogen for approximately 30 minutes. After 30 minutes, ether was added slowly to the mixture, until it became cloudy and a white precipitate formed. Solid was collected by filtration and washed with ether (3 x 10 mL). The collected solid was then dried in vacuum oven to give 3-(3-chloro~4-isopropoxyphenyl)-5-(isoindolin-5-yl)-I,2,4-oxadiazole as the TFA salt (26.7mg, 62.6%). LCMS (Table 1, Method c) R, = 2.29 min, m/z 356.17 (M+H)+. 1H NMR (400 MHz, DMSO) δ ppm 9.46 (s, 2H), 8.27 (s, 1H), 8.20 (d, 1H), 8.00 (d, 1H), 7.70 (d, 1H), 7.41 (d, 1H), 4.83 (sept, 1H), 4.64 (d, 4H), 1.35 (d, 6H). Example #52: Preparation of methyl 3-(5-(3-(3-chloro-4-isopropoxyphenyI)-l,2,4-oxadiazol-5-yI)isoindolin-2-yl)propanoate (Formula Removed) 3-(3-chloro-4-isopropoxyphenyl)-5-(isoindolin-5-yl)-l,2>4-oxadiazole (16.7mg, 0.047 mmol) was added to a 2mL microwave vial equipped with a stirring bar. Methyl acrylate (8.45 µL, 0.094 mmol), and methanol (1.0 mL) were added, the vial capped, and the reaction heated to 90°C for 20min under microwave irradiation (300W). After 20 minutes, another aliquot of methyl acrylate (8.45 uL, 0.094 mmol) was added, the vial was re-sealed, and heated to 110°C for 40 min under microwave irradiation (300W). Reaction was then concentrated and dried under vacuum overnight to give crude methyl 3-(5-(3-(3-chloro-4-isopropoxyphenyl)-1,2,4-oxadiazol-5-yl)isoindolin-2-yl)propanoate as a yellow oil (21.6 mg, 104%). The product was used without further purification. LCMS (Table 1, Method c) R, = 2.85 min, m/z 442.45 (M+H)+ Example #53: Preparation of 3-(5-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)isoindolin-2-yl)propanoic acid, Hydrochloric Acid (Formula Removed) To a solution of methyl 3-(5-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)isoindolin-2-yl)propanoate (21mg, 0.048 mmol) in ethanol (1 ml) was added 2M aqueous NaOH (1 ml, 2.000 mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen for approximately 4 hours. Reaction mixture was then acidified to a pH of 1 by addition of 2N HC1, at which time a precipitate formed. The solid was collected by filtration and washed with water (3x 5 mL). The solid was then dried in a vacuum oven overnight to give 3-(5-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)isoindolin-2-yl)propanoic acid as the hydrochloride salt (10.2 mg, 46.2%). LCMS (Table 1, Method c) R, = 1.86 min, m/z 428.20 (M+H)+. 1H NMR (400 MHz, DMSO) δ ppm 12.12 (m, 1H), 8.23 (s, 1H), 8.19 (d, 1H), 8.07 (d, 1H), 8.01 (dd, 1H), 7.68 (d, 1H), 7.41 (d, 1H), 4.83 (sept, 1H), 4.72 (s, 4H), 3.58 (t, 2H), 2.84 (t, 2H), 1.36 (d, 6H) Example #54: Preparation of (Z)-methyl 3-(4-(3-(3-chloro-4-isopropoxyphenyI)-l,2,4-oxadiazol-5-yl)phenyl)acrylate (Formula Removed) A two-neck round bottom flask was charged with methyl 2-(bis(2,2,2-trifluoroethoxy)phosphoryl)acetate (0.235 ml, 1.109 mmol), 18-crown-6 (1465 mg, 5.54 mmol) and THF (15 ml). The mixture was then cooled to -78°C under an atmosphere of nitrogen. Potassium bis(trimethylsilyl)amide (221 mg, 1.109 mmol) was added and the mixture stirred for a few minutes. 4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5- yl)benzaldehyde (380 mg, 1.109 mmol) was added and the mixture stirred at -78°C for 90 minutes and then left to warm to room temperature overnight. Reaction was quenched by the addition of saturated NH Cl (aqueous). Mixture was separated and the aqueous layer was extracted with ether (3 x lOmL). Combined organics were dried over MgSO4 and concentrated to give an off-white solid. Solid was triturated with MeOH and collected by vacuum filtration and washed with MeOH (3 x 10 mL). Collected solid was dried overnight in a vacuum oven to give (Z)-methyl 3-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)acrylate (325 mg, 73.5%). LCMS (Table 1, Method c) R, = 3.22 min, m/z 399.16 (M+H)+. 1H NMR (400 MHz, DMSO) δ ppm 8.18 (d, 2H), 8.06 (d, 1H), 8.01 (dd, 1H), 7.79 (d, 2H), 7.40 (d, 1H), 7.18 (d, 1H), 6.84 (d, 1H), 6.20 (d, 1H), 4.83 (sept, 1H), 3.67 (s, 3H), 1.35 (d, 6H). Example #55: Preparation of (Z)-3-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)acrylic acid (Formula Removed) To a solution of (Z)-methyl 3-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)acrylate (30mg, 0.075 mmol) in EtOH (2 mL) was added 2N aqueous NaOH (2mL). The reaction was stirred at room temperature, under nitrogen, for 2 hours. Reaction was acidified via addition of IN HC1, until a precipitate formed. Solid was collected by filtration, washed with 0.2N HC1, and dried in a vac oven to give (Z)-3-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)acrylic acid (8.2mg, 28.3%). LCMS (Table 1, Method c) R, = 2.64 min, m/z 385.12 (M+H)+. 1H NMR (400 MHz, DMSO) δ ppm 13.11-12.20 (m, 1H), 8.15 (d, 2H), 8.04 (d, 1H), 7.99 (dd,, 1H), 7.78 (d, 2H), 7.37 (d, 1H), 7.03 (d, 1H), 6.12 (d, 1H), 4.81 ( sept., 1H), 1.33 (d, 6H) Example #56: Preparation of 3-chloro-4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)aniline (Formula Removed) (Z)-3-chloro-N'-hydroxy-4-isopropoxybenzimidamide (0.5 g, 2.187 mmol), 4-amino-2-chlorobenzoic acid (0.413 g, 2.405 mmol), DCC (0.496 g, 2.405 mmol), HOBT (0.368 g, 2.405 mmol) were placed in an 80ml microwave vial and Acetonitrile (12.01 mi) was added. The reaction mixture was stirred for 5 minutes at room temperature before the addition of DDEA (0.840 ml, 4.81 mmol). The reaction mixture was heated to 120 °C for 30 min in a microwave. TLC (50%EA/Hept) indicated 4 spots Rf 0.8,0.6,0.5 and 0.3. LCMS (2007_9349) indicated by UV 16% (2.61 mins) to (M+H) 364.31. The solvent was removed and the crude material purified by FCC (50%EA/Hept) to afford 3-chloro-4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)aniline (534 mg, 1.466 mmol, 67.1 % yield). LCMS (Table A, Method b) indicated a 99% by UV (3.10 mins) and 92% by ELSD (3.06 mins) to (M+H)+364.12. Example #57: Preparation of 3-(3-chIoro-4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenylamino)cyclobutanecarboxylicacid (Formula Removed) 3-chloro-4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)aniline (200 mg, 0.549 mmol) and 3-oxocyclobutanecarboxylic acid (62.7 mg, 0.549 mmol) in methanol (1280 µl) at room temperature was added acetic acid (842 µl, 14.72 mmol). The reaction mixture was stirred at room temperature for 10 minutes before addition of sodium cyanoborohydride (17.25 mg, 0.275 mmol) as a single portion. The reaction mixture was stirred at room temperature overnight. LCMS (2007_9476) indicated a 43% by ELSD (2.90 min)s conversion to (M+H) 462.16. The solvent was removed and the crude material purified by FCC (50%EA/Hept) to afford 3-(3-chloro-4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-y])phenylamino)cyclobutanecarboxylic acid (135 mg, 0.292 mmol, 53.2 % yield) as a white solid. LCMS (Table A, Method b) indicated 100% by UV (3.06 mins) to (M+H)+ 364.12. Preparation #21:4-(3-(3-chIoro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)aniline (Formula Removed) (Z)-3-chloro-N'-hydroxy-4-isopropoxybenzimidamide (1 g, 4.37 mmol), 4-aminobenzoic acid (0.660 g, 4.81 mmol), HOBT (0.737 g, 4.81 mmol), DCC (0.992 g, 4.81 mmol) and DIEA (1.680 ml, 9.62 mmol) were combined in a microwave vial. The reaction mixture was heated in the microwave for 20 minutes at 150 °C. The reaction mixture was filtered to remove the urea formed in the reaction and the solvent was removed in vacuo. The crude material was purified by FCC (50% ethyl acetate/heptane) to afford 4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)aniline (729 mg, 2.211 mmol, 50.6% yield) as an off white solid: LCMS (Table A, Method b) 3.00 min, (M+H)+ 330.13. Preparation #22:3-(4-(3-(3-chIoro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenylarnino)cyclobutanecarboxylicacid (Formula Removed) 4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)aniline (250 mg, 0.531 mmol) in Methanol (1478 µl) at room temperature was added 3-oxocyclobutanecarboxylic acid (60.5 mg, 0.531 mmol) followed by acetic acid (814 ul, 14.22 mmol). The reaction mixture was stirred at room temperature for 5 minutes before the addition of sodium cyanoborohydride (16.67 mg, 0.265 mmol). The reaction mixture was stirred overnight at room temperature. The solvent was removed and the crude material purified by FCC (50% ethyl acetate/heptane) to afford 3-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5- yl)phenylamino)cyclobutanecarboxylic acid (139 mg, 0.302 mmol, 56.9% yield) as a white solid. LCMS (Table A, Method b) 2.89 min, (M+H)+ 428.20. Example #58: Preparation of 2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)propan-2-amine (Formula Removed) Anhydrous cerium (III) chloride (5.57 g, 22.60 mmol) and anhydrous tetrahydrofuran (20 mL) were added to a dry 2-neck round bottom flask under nitrogen. The resulting suspension was sonicated for a few minutes and then stirred at room temperature for 90 minutes. The mixture was then cooled to -50 °C, and methylithium (14.13 mL, 22.60 mmol) was added slowly. After 60min, and warming to 0 °C, the reaction was cooled to -50 °C and 4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)benzonitrile (2.4g, 7.06 mmol) (preparedby General Procedure X) in 8mL of anhydrous THF was added drop-wise, to keep the temperature of the reaction at -50 °C. The reaction was maintained at -50C for 1 hr, then left to warm to room temperature overnight. The next day the reaction was cooled to -50 °C, and quenched by the addition of 21 mL of 35% NH,OH. The quenched reaction was left to warm to room temperature over two hours. The mixture was filtered through Celite® and washed with DCM (4x 60mL). The filtrate was collected and then washed with water and dried over MgSO4. Solvent was removed under reduced pressure and the crude material was purified by RP-HPLC (A = 50mM ammonium acetate, B = acetonitrile; 30-70% B over 30.0 min (21.0 mL/min flow rate); 21.2 x 250 mm Thermo Hyperprep C18 column, 8 µm panicles) to give 2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)propan-2-amineaslhe acetic acid salt (309 mg; 10.1%). LCMS (Table 1, Method a) R, = 2.61 min; 1H NMR (400 MHz, DMSO-d6) δ ppm 8.14-7.94 (m, 4H), 7.80 (d, J = 8.43 Hz, 2H), 7.37 (d, J = 8.81 Hz, 1H), 4.80 (sept, J = 6.04 Hz, 1H), 1.85 (s, 3H), 1.39 (s, 6H), 1.36-1.31 (d, J = 6.04 Hz, 6H) Preparation #23: methyl 3-(2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)pbenyl)propan-2-ylamino)propanoate (Formula Removed) 2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yI)phenyl)propan-2-amine, acetic acid (132 mg, 0.306 mmol) was added to a 5 mL microwave vial equipped with a stirring bar. Methyl acrylate (52.6 mg, 0.611 mmol), and MeOH (3.0 mL) were added, the vial capped, and the reaction heated to 120 °C for 90 min under microwave irradiation (Biotage Optimizer, 300 W). After 90 min another aliquot of methyl acrylate (52.6 mg, 0.611 mmol) was added and the reaction submitted for another 60 min at 120°C. Reaction was cooled and the solvent removed under reduced pressure. Crude material was purified by RP-HPLC (A = 50mM ammonium acetate, B = acetonitrile; 30-70% B over 30.0 min (21.0 mL/min flow rate); 21.2 x 250 mm Thermo Hyperprep C18 column, 8 µm particles) to give methyl 3-(2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)propan-2-ylamino)propanoate(93.5 mg; 59.7%). LCMS (Table 1, Method f) R, = 2.78 min, m/z = 458.29 (M=H)+; Example #59: Preparation of 3-(2-(4-(3-(3-chloro-4-isopropoxyphenyI)-l,2,4-oxadiazol-5-yl)phenyl)propan-2-ylamino)propanoic acid (Formula Removed) Methyl 3-(2-{4-{3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)propan-2-ylamino)propanoate (83mg, 0.181 mmol) was dissolved in ethanol (4mL) and NaOH (4mL, 8.00 mmol) was added. The mixture was stirred at room temperature under nitrogen. After 20 minutes the reaction was neutralized by drop-wise addition of acetic acid. The aqueous mixture was then frozen and lyophilized. The solid obtained after lyophilization was brought up in DCM, filtered, and washed with DCM. The filtrate was concentrated and brought up in ether to provide a slightly cloudy solution. IN HC1 in ether was added dropwise until white precipitate formed. Material was collected by filtration, washed with ether, and dried in a vacuum oven to give 3-(2-(4-(3-(3-chloro-4-isopropoxyphenyl)-l,2,4-oxadiazol-5-yl)phenyl)propan-2-ylamino)propanoic acid as the hydrochloric acid salt (61.5 mg; 70.6%). LCMS (Table 1, Method f) R, = 1.98 min, m/z = 444.29 (M=H)+; 1H NMR (400 MHz, DMSO-d6) δ ppm 8.32 (d, J = 8.57 Hz, 2H), 8.12 (d, J = 2.08 Hz, 1H), 8.03 (dd, J = 8.64, 2.10 Hz, 1H), 7.85 (d, J = 8.59 Hz, 2H), 7.25 (d, J = 8.78 Hz, 1H), 4.79 (sept, J = 6.11 Hz, 1H), 2.95 (t, J = 6.20 Hz, 2H), 2.44 (t, J = 6.17 Hz, 2H), 1.84 (s, 6H), 1.40 (d, J = 6.04 Hz, 6H) What is claimed is: 1. A compound of Formula I (Formula Removed) pharmaceutically acceptable salts, biologically active metabolites, solvates, hydrates, prodrugs, enantiomers or stereoisomers thereof, wherein Lisa bond or optionally substituted (C1-C3)alkyl; R1 is -C(O)-NH-phenyl, -NH-C(O)-furanyl, -NH-S(O)2-optionally substituted phenyl, -O-optionally substituted (C1-C3)alkyl, -S-optionally substituted (C1-C3)alkyl, optionally substituted (C2-C6)alkyl, optionally substituted amino, optionally substituted (C3-C6)cycloalkyl, -(CH2)(C3)alkyl, tetrahydrobenzofuranyl, furanyl, tetrahydrofuranyl, optionally substituted 2,3-dihydroisoindolyl, optionally substituted imidazolyl, optionally substituted indolyl, optionally substituted isoxazolyl, optionally substituted morpholinyl, optionally substituted naphthyl, optionally substituted phenyl, -O-CH2-phenyl, -O-phenyl, -O-optionally substituted phenyl, optionally substituted piperidinyl, optionally substituted pyrazolyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrrolidinyl, optionally substituted 1,2,3,4-tetrahydroisoquinolinyl, optionally substituted quinolinyl, optionally substituted 5,6,7,8-tetrahydroimidazo[l,2-a]pyrazinyl, optionally substituted pyrrolyl, optionally substituted quinolinyl, optionally substituted thiazoly! or optionally substituted thienyl, R2 is Br, Cl, CF3, CN, or -O-(C1-C2)alkyl; R3 is optionally substituted-(C3-C8)aIkyl, (C4-C5)alkenyI, (C4-C5)alkynyl, optionally substituted-(C3-C6)cycloalkyl, -(C2-C3)alkyl-O-optionally substituted (C1.C3)alkyl, -(C1-C3)alkyl-imidazolyl, -(C1-C3)alkyl-morpholinyl, -(C1-C3)alkyl-optionally substituted phenyl, -(C1-C3)aIkyl-optionally substituted piperazinyl, -(C1-C3)alkyl-pyrrolidinyl, -(C1-C3)alkyl-piperidinyl, -(C1-C3)alkyl-thienyl, tetrahydrofuranyl or thiazoly I; and R6 is H; provided that R1 is not substituted by optionally substituted cyclohexyl, -C(O)-cyclohexyl or -NH-cyclohexyl; when L is (C1-C3)alkyl, R1 is not optionally substituted isoxazolyl; when R3 is optionally substituted (Ci)alkyl, L-R1 is not cyclohexyl or -CH2-cyclohexyl; and provided that the compound is not (Formula Removed) 2. The compound of claim 1 wherein R1 is optionally substituted by one or more substituents independently selected from Br, Cl, F, CF3, CN, oxo, optionally substituted (C1-C6)alkyl, optionally substituted (C2-C6)alkenyl, optionally substituted amino, optionally substituted (C3-C6)cycloalkyl, -CH2-optionalIy substituted piperidinyl, -C(O)- optionally substituted (C1-C6)alkyl, -C(O)-NR-(C1-C6)alkyl, -C(O)-O-optionally substituted(C1-C6)alkyl, -O- optionally substituted (C1-C6)alkyl, -NH-(C3-C6)cycloalkyl, -NH-C(O)—O-(C1-C3)alkyl, -S(O)2-N(R9)2, -S(O)2-NH-optionally substituted (C1-C4)alkyl, -NH-optionally substituted(C1-C6)alkyl, -NH-C(O)-furanyl, -NH-S(O)2-optionally substituted phenyl, optionally substituted pyridinyl, (Formula Removed) wherein R is H or (C1-C3)lkyl; and wherein each R9 is independently selected from H or optionally substituted (C1-C6)alkyl. 3. The compound of claim 2 wherein the compound is a compound of Formula la (Formula Removed) wherein L is a bond. 4. The compound of claim 3 wherein R1 is optionally substituted phenyl or optionally substituted indolyl. 5. The compound of claim 4 wherein the compound is (Formula Removed) wherein y is 1 or 2. 6. The compound according to claim 1 wherein L is optionally substituted (C1-C3)alkyl; R1 is -C(O)-NH-phenyl, -NH-C(O)-furanyl, -NH-S(O)2-optionally substituted phenyl, optionally substituted -O-(C1-C3)alkyl, -S-(C1-C3)alkyl, benzyloxy, optionally substituted(C3-C6)cyc:loalkyl, optionally substituted imidazolyl, morpholinyl, optionally substituted naphthyl, optionally substituted phenyl, optionally substituted phenoxy, optionally substituted piperazinyl, optionally substituted piperidinyl, optionally substituted pyridinyl, optionally substituted pyrrolidinyl or optionally substituted thienyl; R2 is Cl; R3 is isopropyl; and R6 is H. 7. The compound according to claim 6 wherein L is CH2 and R1 is optionally substituted phenyl or optionally substituted (C3-C6)cycloalkyl. 8. The compound according to claim 7 wherein R1 is substituted by one or more substituents independently selected from F, dimethylamino and phenoxy. 9. A compound of formula II (Formula Removed) pharmaceutically acceptable salts, biologically active metabolites, solvates, hydrates, prodrugs, enantiomers or stereoisomers thereof, wherein Y is a bond; L is a bond or CH2; R1 is optionally substituted (C1-C4)alkyl, optionally substituted indolyl or optionally substituted phenyl; R2 is CF3; R3 is H, morpholinyl or (C3-C5)cycloalkyl; and R6 is H. 10. The compound according to claim 9 wherein R1 is optionally substituted phenyl and R3 is morpholinyl. 11. The compound of claim 10 wherein R1 is optionally substituted by one or more substituents independently selected from Cl, optionally substituted (C1-C3)alkyl, (Formula Removed) 12. A compound of Formula III (Formula Removed) pharmaceutically acceptable salts, biologically active metabolites, solvates, hydrates, prodrugs, enantiomers or stereoisomers thereof, wherein DisCHorN; Y is a bond; L is a bond; R1 is optionally substituted phenyl; R2 is H; R3 is H; and R6 is optionally substituted (C1-C3)alkyl. 13. The compound according to claim 12 wherein R1 is substituted with Cl and isopropoxy. 14. A compound having formula (IV): (Formula Removed) or a pharmaceutically acceptable salt, solvate, hydrate, metabolite, prodrug, enantiomer or stereoisomer thereof, wherein: X is N or CR4, L is a bond, -CH2CH2-, (C3-C6)cycloalkyl, or -CHR3; Y is -O-, -NR7- or -C(R7)(R7')-; R1 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted -(C1-C6)alkyl-O-(C1-C3)alkyl, optionally substituted -(C1-C6)alkyl-O-(C1-C6)alkyl -O-(C1-C3)alkyl, optionally substituted -(C1-C6)alkyl-O-aryl, alkylsulfanylalkyl, unsubstituted (C2-C3)alkyl, substituted (C1-C6)alkyl, -COR9, optionally substituted -O-(C1-C3)alkyl, -N(R7)(R8), -N(R7)SO2-R9 or optionally substituted (C3-C6)ycloalkyl, and wherein R1 is not substituted cyclopentathiophene, halothiophene, substituted indan or substituted chromenone; R2 and R6 may be the same or different and are independently H, -(C1-C4)alkyl, -O-(C1-C3)alkyl, -CF3, -CN, halo or -COO-(C1-C4)alkyl; R3 is optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted (C3-C6)cycloalkyl, -(CH2)n-R9, -CO-OR9, -CO-R9, -CON(R7)(R9), -N(R7)(R9), -SOR9 , -SO2R9 and optionally substituted straight or branched (C1-C8)aIkyl chain optionally including -CO-, -COO-, -SO-, -SO2-, -CONH-, -NHCO-, -N- or -O- groups embedded within the alkyl chain; and when Y is O, R3 is not alkyldiazeapane, -C(CH3)2COOCH2CH3 or -CH2CH2N(CH2CH3)2, and when Y is -CH2-, R3 is not -CH2COOH; or Y is a bond and R3 is optionally substituted morpholino; R4 is H, -(C1-C4)alkyl, -O-(C1-C3)alkyl, -CF3, -CN or halo; R5 is H, O-(C1-C3)alkyl or (C1-C3)alkyl; each occurrence of R7 or R7 is independently H or optionally substituted (C1-C3)alkyl; R8 is H, optionally substituted CH3, or -COR9; R9 is hydrogen, optionally substituted (C1-C3)alkyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl or optionally substituted (C3-C6)cycloalkyl; and nis 1,2, 3 or 4; provided that R1 is not optionally substituted furanyl or -C(O)-optionally substituted furanyl; R3 is not optionally substituted quinolinyl; R9 is not optionally substituted cyclopropyl, optionally substituted cyclohexyl, optionally substituted furanyl, optionally substituted imidazolyl, optionally substituted indolyl, optionally substituted naphthyl, optionally substituted piperazinyl, optionally substituted pyrazolyl, optionally substituted pyridazinyl or optionally substituted quinolinyl; R1 is not substituted by -C(O)-cyclopentyl, optionally substituted cyclopentyl, -C(O)-cyclobutyl, cyclobutyl, -C(O)-cyclohexyl or optionally substituted cyclohexyl; R3 is not substituted by -C(O)-cyclopropyl; when R3 is CH3 or 4-chlorophenylmethyl, L-R1 is not cyclopropyl, cyclopentyl, optionally substituted cyclohexyl, -CH2-cyclohexyl, -NH-cyclohexyl, -CH2CH2-cyclohexyl or optionally substituted pyrazolyl; when Y is O, R3 is not -(C0-C4)alkyl-optionally substituted isoxazolyl or optionally substituted pyrazolyl; when L is (C1-C3)alkyl, R1 is not optionally substituted isoxazolyl; when L is a bond, R1 is not optionally substituted cyclobutyl, optionally substituted cyclohexyl, optionally substituted naphthyl, -CH2-optionally substituted naphthyl, -CH2-O-optionally substituted naphthyl, optionally substituted pyrazolyl or tetrahydrobenzofuranyl; the compound is not (Formula Removed) the compound is not (Formula Removed) wherein R3 is optionally substituted piperazinyl or optionally substituted phenyl; the compound is not (Formula Removed) wherein R1 is optionally substituted pyridine or 3-chlorophenyl and -Y-R3 is -NH-C(O)-optionally substituted phenyl; -O-optionally substituted pyridinyl; -NH-C(O)-OCH3; -CH2-optionally substituted piperazinyl; -O-optionally substituted (C1-C9)alkyl; -CH2-morpholinyl; or -O-C(O)-optionally substituted pyridinyl; provided the compound is not (Formula Removed) wherein L is CH2, CH(CH3) or CH2CH2; Y is O or CH2; R2isHorOCH3; R3 is CH3 or OCF3; and RisHorNO2; provided the compound is not (Formula Removed) provided the compound is not (Formula Removed) wherein R1 is phenyl, 4-chlorophenyl, piperidinyl or thienyl. 15. The compound of claim 14 wherein each substituent or optional substituent is independently one or more R10 groups wherein R10 is optionally substituted alkyl, alkenyl, optionally substituted alkoxy groups, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylheterocycloalkoxy, alkyl, alkylamino, alkylcarbonyl, alkylester, alkyl-O-C(O)-, alkyl-heterocyclyl, alkyl-cycloalkyl, alkyl-nitrile, alkylsulfonyl, alkynyl, amido groups, amino, aminoalkyl, aminoalkoxy, aminocarbonyl, carbonitrile, carbonylalkoxy, carboxamido, CF3, CN, -C(O)OH, -C(O)H, -C(O)-C(CH3)3, -OH, -C(O)O-alkyl, -C(O)O-cycloalkyl, -C(O)O-heterocyclyl, -C(O)-alkyl, -C(O)-cycloalkyl, -C(O)-heterocyclyl, CN, cycloalkyl, dialkylamino, dialkylaminoalkoxy, dialkylaminocarbonylalkoxy, dialkylaminocarbonyl, dialkylaminosulfonyl, -C(O)-ORa, halogen, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, hydroxy, hydroxyalkyl, nitro, oxo, phenyl, -SO2CH3, -SO2CF3. sulfonyl, tetrazolyl, thienylalkoxy, trifluoromethylcarbonylamino, trifluoromethylsulfonamido, heterocyclylalkoxy, heterocyclyl-S(O)p, cycloalkyl-S(O)p, alkyl-S-, heterocycIyl-S, heterocycloalkyl, cycloalkylalkyl, heterocycolthio, cycloalkylthio, N-alkylamino and N,N-dialkylamino where R3 is alkyl, heterocycloalkyl, or heterocyclyl and p is 1 or 2. 16. The compound of claim 14 having formula (IVa): (Formula Removed) or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: L is a bond, -CH2CH2- or (C3-C6)cycloalkyl; R1 is optionally substituted aryl, optionally substituted heteroaryl or optionally substituted -O-(C1-C3)alkyl; R2 is a halogen or CF3; and R3 is straight or branched optionally substituted (C2-C8)alkyl, or optionally substituted (C3-C6)cycloalkyl. 17. The compound of claim 16 wherein R2 is Cl or CF3. 18. The compound of claim 17 wherein R2 is Cl. 19. The compound of claim 14 having formula (IVb): (Formula Removed) or a physiologically acceptable salt, solvate, hydrate, prodrug, enantiomer or stereoisomer thereof, wherein: L is a bond, -CH2CH2-, or (C3-C6)cycloalkyl; R1 is tolyl, pyridinyl, isoxazolyl, pyrazinyl, methylpyrazinyl, ethanonylphenyl, phenyl carbamic acid tert-butyl ester, benzonitrile, diethylaminophenyl, thiophenyl, N-methylpyrrolyl, halopyridinyl, or methylpyridinyl; and R3 is isobutyl, cyclopropylmethyl, 3-methoxypropyl, 1-ethylpropyl, sec-butyl, isopropyl, tertbutyl, or trifluorethyl. 20. The compound of claim 14 having formula (IVc): (Formula Removed) or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: L is a bond or -CH2CH2-; R1 is tolyl, pyridinyl, methylpyrazinyl, phenyl carbamic acid tert-butyl ester, benzonitrile, thiophenyl, N-methylpyrrolyl, or halopyridinyl; and R3 is isobutyl, isopropyl, cyclopropylmethyl, 3-methoxypropyl, 1-ethylpropyI, sec-butyl, or isopropyl. 21. The compound of claim 20, wherein R3 is isopropyl. 22. The compound of claim 21, wherein R1 is tolyl or halopyridinyl. 23. The compound of claim 22, wherein R1 is chloropyridinyl or fluropyridinyl. 24. A pharmaceutical composition comprising a compound according to claim 1,9, 12 or 14 or a pharmaceutically acceptable salt, solvate, hydrate, metabolite, prodrug or stereoisomer thereof and a pharmaceutically acceptable diluent or carrier. 25. Use of the compounds claim 1, 9, 12 or 14 or a pharmaceutically acceptable salt, solvate, hydrate, metabolite, prodrug or stereoisomer thereof for the manufacture of a medicament for treating an immune disorder comprising administering to a subject in need thereof a therapeutical ly effective amount of one or more compounds of. 26. The use of claim 25 wherein the immune disorder is an autoimmune disorder. 27. The use of claim 26 wherein the autoimmune disorder is rheumatoid arthritis, active chronic hepatitis, Addison's Disease, anti-phospholipid syndrome, atopic allergy, autoimmune atrophic gastritis, achlorhydra autoimmune, Celiac Disease, Crohn's Disease, Gushing's Syndrome, dermatomyositis, Goodpasture's Syndrome, Grave's Disease, Hashimoto's thyroiditis, idiopathic adrenal atrophy, idiopathic thrombocytopenia, Lambert-Eaton Syndrome, lupoid hepatitis, mixed connective tissue disease, pemphigoid, pemphigus vulgaris, pernicious anemia, phacogenic uveitis, polyarteritis nodosa, primary biliary cirrhosis, primary sclerosing cholangitis, psoriasis, Raynaud's, Reiter's Syndrome, relapsing polychondritis, Schmidt's Syndrome, Sjogren's Syndrome, sympathetic ophthalmia, Takayasu's Arteritis, temporal arteritis, thyrotoxicosis, lupus, rheumatoid arthritis, Type B Insulin Resistance, ulcerative colitis, or Wegener's granulomatosis. 28. Use of one or more compounds of claim 1, 9,12 or 14 or a pharmaceutically acceptable salt, solvate, hydrate, metabolite, prodrug or stereoisomer thereof for the manufacture of a medicament for treating a central nervous system disorder. 29. Use of one or more compounds of claim 1,9,12 or 14 or a pharmaceutically acceptable salt, solvate, hydrate, metabolite, prodrug or stereoisomer thereof for the manufacture of a medicament for treating multiple sclerosis.